• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ethos Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    2/25/26 4:05:00 PM ET
    $LIFE
    Specialty Insurers
    Finance
    Get the next $LIFE alert in real time by email
    • Records full-year revenue of $387.6 million, growing 52% year-over-year
    • Achieves Net Income of $24.6 million and Adjusted EBITDA of $25.8 million in Q4, reflecting a 22% margin and a 23% Adjusted EBITDA margin
    • Delivers third consecutive year of revenue growth greater than 50%



    AUSTIN, Texas, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025.

    "We delivered a strong close to 2025 with 65% year-over-year revenue growth in Q4," said Peter Colis, CEO and Co-Founder of Ethos. "Our financial results demonstrate not only exceptional topline growth but also continued evidence of Ethos' significant earnings potential. We are on a mission to protect families by democratizing access to life insurance, and reaching the milestone of 500,000 policies activated is a testament to that deep commitment."

    Fourth Quarter 2025 Financial Highlights

    • Revenue: Grew 65% year-over-year to $110.1 million
    • Direct Channel Revenue: Grew 93% year-over-year to $74.2 million
    • Third-Party Channel Revenue: Grew 27% year-over-year to $35.9 million
    • Net Income: $24.6 million, representing a 22% margin
    • Adjusted EBITDA: $25.8 million, representing a 23% margin
    • Gross Profit: $108.0 million, representing a 98% gross profit margin
    • Contribution Profit: $47.2 million, a 43% contribution profit margin
    • Net Income per Share: diluted, was $0.42 per share, a 163% improvement year-over-year, compared to $0.16 per share in the fourth quarter of 2024
    • Cash Flow: Net cash generated from operations was $4.9 million



    Full Fiscal Year 2025 Financial Highlights

    • Revenue: Grew 52% year-over-year to $387.6 million
    • Direct Channel Revenue: Grew 40% year over year to $242.5 million
    • Third-Party Channel Revenue: Grew 79% year-over-year to $145.1 million
    • Net Income: $71.2 million, representing an 18% margin
    • Adjusted EBITDA: $89.0 million, representing a 23% margin
    • Gross Profit: $380.9 million, representing a 98% gross profit margin
    • Contribution Profit: $162.0 million, a 42% contribution profit margin
    • Net Income per Share: diluted, was $1.22 per share, a 44% improvement year-over-year, compared to $0.85 per share in the year ending December 31, 2024
    • Cash Flow: Net cash generated from operations was $36.2 million
    • Cash, cash equivalents, and investments: $157.4 million as of December 31, 2025



    Recent Business Highlights

    • Families Protected: Activated 54,714 new policies in Q4 (42% growth), bringing the total lifetime policies to over 500,000
    • Agent Ecosystem Expansion: Ended 2025 with over 15,000 agents selling on the platform
    • Product Innovation: Launched two new products in Q4 - Accumulation Indexed Universal Life with North American Sammons and Cancer Insurance with Aflac.
    • Carrier Network: Ended the quarter with six carriers



    Financial Outlook

    For the first quarter of 2026, Ethos expects the following:

    • Total Revenue: Between $144.0 million and $146.0 million, representing a 53% increase year-over-year at the midpoint
    • Adjusted EBITDA: Between $30.0 million and $32.0 million



    For the full fiscal year 2026, Ethos expects the following:

    • Total Revenue: Between $510.0 million and $514.0 million, representing a 32% increase year-over-year at the midpoint
    • Adjusted EBITDA: Between $99.0 million and $103.0 million



    Ethos' financial outlook for the first quarter and full fiscal year 2026 are forward-looking, and actual results may differ materially as a result of many factors. Refer to the Forward-Looking Statements safe harbor below for information on the factors that could cause the company's actual results to differ materially from these forward-looking statements.

    Reconciliation of Adjusted EBITDA on a forward-looking basis to net income, the most directly comparable GAAP measure, is not available without unreasonable efforts due to high variability and complexity and low visibility with respect to certain charges excluded from this non-GAAP measure, including interest expense and interest income and income tax expenses. Ethos expects the variability of these items could have a significant, and potentially unpredictable, impact on its future GAAP financial results.

    Conference Call Information

    Ethos will host a conference call for analysts and investors to discuss its earnings results for the fourth quarter and fiscal year 2025 and outlook for its fiscal first quarter and fiscal year 2026 today at 1:30 p.m. Pacific time (4:30 p.m. Eastern time). A live webcast and accompanying presentation can be accessed through the events section of the Ethos investor relations website at investors.ethos.com. A recorded webcast of the event will also be available on the Ethos Investor Relations website.

    Non-GAAP Financial Information

    Ethos has provided in this press release financial information that has not been prepared in accordance with generally accepted accounting principles in the United States (GAAP). We believe that non-GAAP financial measures, among others, provide important supplemental information to management and investors, help evaluate our business, identify trends affecting our performance, formulate business plans, and make strategic decisions.

    The presentation of these non-GAAP financial measures is not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP. For further information regarding these non-GAAP measures, including the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, please refer to the financial tables below.

    Adjusted EBITDA - Ethos defines Adjusted EBITDA as net income excluding interest expense, interest income, income tax expense, depreciation and amortization, and stock-based compensation expense as set forth in the table below. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA for a period by revenue for the same period. Ethos uses Adjusted EBITDA and Adjusted EBITDA Margin to assess performance, to inform the preparation of its annual operating budget and quarterly forecasts, to evaluate the effectiveness of its business strategies, and to assist its board of directors in monitoring its business and financial performance. Ethos believes that Adjusted EBITDA and Adjusted EBITDA Margin provide useful information to investors about its business and financial performance, enhance their overall understanding of its past performance and future prospects, including by providing consistency and comparability with its past financial performance, and allow for greater transparency with respect to measures used by its management in investors' financial and operational decision making. In addition, Ethos believes Adjusted EBITDA is widely used by investors, securities analysts, and other parties in evaluating companies in its industry as a measure of operational performance.

    Contribution Profit - Ethos defines Contribution Profit as profit less sales and marketing expense, which includes agent payments and underwriting costs for non-activated policies, plus stock-based compensation related to its employees and overhead costs allocated to sales and marketing expenses. Gross profit is defined as revenue less cost of revenue. Cost of revenue primarily consists of underwriting costs associated with activated policies. Overhead costs allocated to sales and marketing expenses include professional fees, technology expenses, and other related costs. Contribution Margin is calculated by dividing Contribution Profit for a period by revenue for the same period.

    Non-GAAP Net Income and Non-GAAP Net Income Per Share, Basic and Diluted - Ethos defines non-GAAP net income as net income, adjusted to exclude stock-based compensation-related charges, in order to provide investors and management with greater visibility to the underlying performance of its recurring core business operations. Ethos defines non-GAAP net income per share, basic, as non-GAAP net income divided by the weighted-average shares outstanding. Ethos defines non-GAAP net income per share, diluted, as non-GAAP net income divided by the weighted-average shares outstanding, which includes the dilutive effect of potentially diluted common stock equivalents outstanding during the period, if any.

    About Ethos

    Ethos is a leading life insurance technology company on a mission to protect families by democratizing access to life insurance and empowering agents at scale. With its robust three-sided technology platform, Ethos is transforming the life insurance experience for consumers, agents, and carriers alike. Ethos offers instant, accessible products and a seamless online process that requires no medical exams and just a few health questions; it eliminates traditional barriers, making it easier than ever for everyone to protect their families. Ethos is redefining how life insurance is bought, sold, and underwritten.

    Learn more at ethos.com.

    Investor Relations Contact:

    Aaron Turner

    [email protected]

    Press Contact:

    Allyson Savage

    [email protected]

    Forward-Looking Statements

    This press release and the related conference call contain express and implied "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Ethos' financial outlook for for the fiscal quarter ending March 31, 2026 and the fiscal year ending December 31, 2026, the size of Ethos' market opportunity, market trends, and Ethos' business and financial strategy and plans. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "project," "will," or similar expressions. Such statements are subject to risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. These include, but are not limited to: Ethos' limited operating history at its current scale, scope and complexity; the growth rate of the markets in which Ethos competes; Ethos' ability to effectively manage and sustain its growth; Ethos's ability to compete with existing competitors and new market entrants; Ethos' ability to attract new and retain existing carriers and agency counterparties; adoption of and engagement with Ethos' platform by individual agents; Ethos' brand awareness and the success of its marketing efforts to grow its business; potential damage to Ethos' reputation; disruptions or other business interruptions that affect the availability of Ethos' platform. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements contained herein are included in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Ethos' prospectus dated January 28, 2026 filed with the Securities and Exchange Commission (SEC) pursuant to Rule 424(b) of the Securities Act of 1933, as amended, on January 30, 2026, as they may be updated by Ethos' subsequent filings with the SEC. Except as required by law, Ethos undertakes no obligation, and does not intend, to update these forward-looking statements.



     
    ETHOS TECHNOLOGIES INC.

    Condensed Consolidated Statements of Operations

    (In Thousands, Except Per Share Data) (Unaudited)
     
      Three months Ended

    December 31,
     Year Ended

    December 31,
      2024  2025  2024  2025 
       
    Revenue:              
    Commission $66,524  $110,077  $254,926  $387,608 
    Total revenue  66,524   110,077   254,926   387,608 
         
    Costs and expenses:              
    Sales and marketing  40,086   64,113   148,664   229,318 
    General and administrative  4,743   9,233   22,417   39,647 
    Technology (exclusive of amortization)  6,366   8,918   23,133   33,629 
    Cost of revenue  1,558   2,059   6,527   6,733 
    Depreciation and amortization  1,269   1,284   5,438   5,359 
    Total costs and expenses  54,022   85,607   206,179   314,686 
                   
    Income from operations  12,502   24,470   48,747   72,922 
         
    Other income (expense):              
    Interest expense  (138)  (765)  (595)  (3,170)
    Interest income  1,322   1,359   5,599   5,831 
    Other income, net  24   61   185   161 
    Total other income, net  1,208   655   5,189   2,822 
         
    Net income before provision for income taxes  13,710   25,125   53,936   75,744 
    Income tax expense  (4,162)  (564)  (5,104)  (4,593)
    Net income  9,548   24,561   48,832   71,151 
         
    Per share data:              
    Basic net income per share $0.60  $1.48  $3.05  $4.31 
    Diluted net income per share $0.16  $0.42  $0.85  $1.22 
    Shares used in computing basic net income per share  16,031   16,600   16,007   16,490 
    Shares used in computing diluted net income per share  58,484   57,886   57,600   58,416 



      
    ETHOS TECHNOLOGIES INC.

    Condensed Consolidated Balance Sheets

    (In Thousands, Except Per Share Data)(Unaudited)

     
      
      As of December 31, 
      2024  2025 
             
    Assets        
    Current assets:        
    Cash and cash equivalents $35,075  $91,091 
    Short-term investments  68,279   34,876 
    Accounts receivable, net  30,303   36,498 
    Commissions receivable-current, net  15,079   28,786 
    Prepaid and other assets  26,070   54,553 
    Total current assets  174,806   245,804 
    Long-term assets:        
    Commissions receivable, net  173,096   224,219 
    Property and equipment, net  7,424   8,189 
    Operating lease right-of-use assets  2,536   2,183 
    Goodwill  2,238   2,238 
    Acquired intangible assets, net of amortization  221   662 
    Long-term investments  35,002   31,468 
    Other long-term assets  558   574 
    Total long-term assets  221,075   269,533 
    Total assets $395,881  $515,337 
       
    Liabilities, redeemable preferred stock and stockholders' deficit        
    Current liabilities:        
    Accounts payable $24,303  $55,070 
    Accrued expenses  19,217   39,224 
    Liabilities related to sale of commissions receivable-current  9,382   11,750 
    Operating lease liabilities-current  753   1,125 
    Other current liabilities  13,945   6,021 
    Total current liabilities  67,600   113,190 
    Long-term liabilities:        
    Liabilities related to sale of commissions receivable-non-current  24,163   12,509 
    Operating lease liabilities-non-current  1,864   1,228 
    Deferred tax liability  3,907   8,529 
    Other long-term liabilities  1,500   - 
    Total long-term liabilities  31,434   22,266 
    Total liabilities  99,034   135,456 
    Commitments and contingencies        
    Redeemable convertible preferred stock, par value $0.0001  403,997   403,997 
    Stockholders' deficit:        
    Common stock, $0.0001 par value  2   2 
    Additional paid-in capital  66,991   78,950 
    Accumulated other comprehensive loss  (478)   (554) 
    Accumulated deficit  (173,665)  (102,514)
    Total stockholders' deficit  (107,150)  (24,116)
    Total liabilities, redeemable convertible preferred stock and stockholders' deficit $395,881  $515,337 



             
    ETHOS TECHNOLOGIES INC.

    Condensed Consolidated Statements of Cash Flows

    (In Thousands)(Unaudited)

             
      Year Ended

    December 31,

      2024  2025 
             
    Cash flows from operating activities      
    Net income $48,832  $71,151 
           
    Adjustments to reconcile net income to net cash provided by (used in) operating activities:        
    Deferred taxes  3,907   4,622 
    Depreciation and amortization  5,438   5,359 
    Non-cash interest expense  595   3,170 
    Accretion of discounts and premium, investments  (3,133)  (1,211)
    Stock-based compensation  3,166   10,596 
    Operating lease right-of-use asset amortization  42   903 
    Unrealized gain foreign currency translation  (199)  (303)
    Changes in operating assets and liabilities:      
    Prepaid and other assets  (23,902)  (21,334)
    Other long-term assets  (378)  (16)
    Accounts payable  12,691   30,631 
    Accounts receivable  (13,626)  (11,195)
    Commissions receivable  (9,166)  (13,707)
    Long-term commissions receivable  (53,851)  (51,123)
    Accrued expenses  7,298   18,920 
    Other current liabilities  12,378   (8,738)
    Other long-term liabilities  (1,000)  (1,500)
    Net cash provided by (used in) operating activities  (10,908)  36,225 
           
    Cash flows from investing activities      
    Purchase of property and equipment  (776)  (1,491)
    Purchase of domain name  (250)  (500)
    Purchase of investments  (154,675)  (66,709)
    Proceeds from maturity of investments  145,003   99,870 
    Sales of investments  13,360   4,983 
    Investment in software development costs  (3,558)  (4,286)
    Net cash provided by (used in) investing activities  (896)  31,867 
         
    Cash flows from financing activities      
    Proceeds from liabilities related to sale of commissions receivable  23,550   5,000 
    Repayment of liabilities related to sale of commissions receivable  (1,902)  (11,952)
    Proceeds from exercise of stock options and warrants  209   1,058 
    Payment of deferred offering costs  —   (6,155)
    Net cash provided by (used in) financing activities  21,857   (12,049)
           
    Net increase in cash and cash equivalents  10,053   56,043 
    Effect of exchange rates on cash  2   (27)
    Cash and cash equivalents, beginning of period  25,020   35,075 
    Cash and cash equivalents, end of period $35,075  $91,091 
           



    ETHOS TECHNOLOGIES INC.

    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

    (In Thousands) (Unaudited)
     
       Three Months Ended

    December 31,
      Year Ended

    December 31,
       2024   2025   2024   2025 
                 
    Gross Profit $64,966  $108,018  $248,399  $380,875 
    Less: Sales and Marketing  (40,086)  (64,113)  (148,664)  (229,318)
    Add: Stock-based Compensation Allocated to Sales and Marketing  297   4   687   2,047 
    Add: Professional Fees Allocated to Sales and Marketing  394   1,631   831   2,805 
    Add: Technology Expenses Allocated to Sales and Marketing  509   880   1,931   3,077 
    Add: Other Expenses Allocated to Sales and Marketing  406   803   1,393   2,549 
    Contribution Profit $26,486  $47,223  $104,577  $162,035 
    Contribution Profit Margin  40%  43%  41%  42%



       Three Months Ended

    December 31,
      Year Ended

    December 31,
       2024   2025   2024   2025 
                 
    Net Income Before Provision for Income Tax $13,710  $25,125  $53,936  $75,744 
    Interest Income  (1,322)  (1,359)  (5,599)  (5,831)
    Interest Expense  138   765   595   3,170 
    Depreciation and Amortization  1,269   1,284   5,438   5,359 
    Stock-based Compensation  897   32   3,166   10,596 
    Adjusted EBITDA $14,692  $25,847  $57,536  $89,038 
    Adjusted EBITDA Margin  22%  23%  23%  23%



       Three Months Ended

    December 31,
       Year Ended

    December 31,
     
       2024   2025   2024   2025 
                     
    GAAP Net Income $9,548  $24,561  $48,832  $71,151 
    Stock-based Compensation  897   32   3,166   10,596 
    Non-GAAP net income $10,445  $24,593  $51,998  $81,747 
                     
    Per Share Data:                
    Weighted average shares used in computing net income per share, basic  16,031   16,600   16,007   16,490 
    Weighted average shares used in computing net income per share, diluted  58,484   57,886   57,600   58,416 
                     
    GAAP net income per share attributable to common stockholders, basic $0.60  $1.48  $3.05  $4.31 
    GAAP net income per share attributable to common stockholders, diluted $0.16  $0.42  $0.85  $1.22 
    Non-GAAP net income per share attributable to common stockholders, basic $0.65  $1.48  $3.25  $4.96 
    Non-GAAP net income per share attributable to common stockholders, diluted $0.18  $0.42  $0.90  $1.40 


    Primary Logo

    Get the next $LIFE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIFE

    DatePrice TargetRatingAnalyst
    2/23/2026$33.00Buy
    Goldman
    2/23/2026$18.00Outperform
    Robert W. Baird
    2/23/2026$21.00Mkt Outperform
    Citizens
    2/23/2026$20.00Overweight
    Barclays
    2/23/2026$23.00Buy
    Deutsche Bank
    2/23/2026$13.00Overweight
    Analyst
    2/23/2026$15.00Buy
    Citigroup
    2/23/2026Outperform
    William Blair
    More analyst ratings

    $LIFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Ethos Technologies with a new price target

    Goldman initiated coverage of Ethos Technologies with a rating of Buy and set a new price target of $33.00

    2/23/26 8:37:19 AM ET
    $LIFE
    Specialty Insurers
    Finance

    Robert W. Baird initiated coverage on Ethos Technologies with a new price target

    Robert W. Baird initiated coverage of Ethos Technologies with a rating of Outperform and set a new price target of $18.00

    2/23/26 8:37:19 AM ET
    $LIFE
    Specialty Insurers
    Finance

    Citizens initiated coverage on Ethos Technologies with a new price target

    Citizens initiated coverage of Ethos Technologies with a rating of Mkt Outperform and set a new price target of $21.00

    2/23/26 8:36:59 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Softbank Group Corp. converted options into 2,697,089 shares (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    2/3/26 9:00:15 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Large owner Accel Growth Fund Iv L.P. converted options into 7,143,886 shares (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    2/2/26 9:08:31 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Large owner Sc Us (Ttgp), Ltd. returned 12,000,124 shares to the company and converted options into 12,000,124 shares (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    2/2/26 6:41:52 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    SEC Filings

    View All

    Ethos Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Ethos Technologies Inc. (0001788451) (Filer)

    2/25/26 4:29:30 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form 8-K filed by Ethos Technologies Inc.

    8-K - Ethos Technologies Inc. (0001788451) (Filer)

    2/2/26 7:02:49 AM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form 424B4 filed by Ethos Technologies Inc.

    424B4 - Ethos Technologies Inc. (0001788451) (Filer)

    1/29/26 9:55:44 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ethos Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    Records full-year revenue of $387.6 million, growing 52% year-over-yearAchieves Net Income of $24.6 million and Adjusted EBITDA of $25.8 million in Q4, reflecting a 22% margin and a 23% Adjusted EBITDA marginDelivers third consecutive year of revenue growth greater than 50% AUSTIN, Texas, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. "We delivered a strong close to 2025 with 65% year-over-year revenue growth in Q4," said Peter Colis, CEO and Co-Founder of Ethos. "Our financial resul

    2/25/26 4:05:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Ethos Files Registration Statement for Proposed Initial Public Offering

    AUSTIN, Texas, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Ethos intends to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol "LIFE." Goldman Sachs & Co. LLC and J.P. Morgan are acting as lead book-running managers for the offering. BofA Securities,

    9/26/25 1:50:31 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Botha Roelof bought $4,949,975 worth of shares (260,525 units at $19.00), converted options into 12,000,124 shares and returned 12,000,124 shares to the company (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    2/2/26 6:36:37 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Director Wheeler William J bought $4,949,975 worth of shares (260,525 units at $19.00), increasing direct ownership by 2,481% to 271,025 units (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    1/30/26 8:49:26 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Director Mullin Mark W. bought $99,997 worth of shares (5,263 units at $19.00), increasing direct ownership by 43% to 17,451 units (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    1/30/26 8:48:09 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors

    AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the appointment of William J. Wheeler to its Board of Directors. Mr. Wheeler, a seasoned executive with deep expertise across insurance, retirement services, and investment banking, joins Ethos' distinguished board, further strengthening Ethos' governance and strategic guidance as the company continues its rapid growth and innovation. Mr. Wheeler brings more than three decades of leadership experience in the financial services industry. He most recently served as Vice Chairman of Athene Holding Ltd. (NYSE:ATH), a leadin

    7/30/25 11:00:00 AM ET
    $EVR
    $LIFE
    $ATH
    Investment Managers
    Finance
    Specialty Insurers
    Life Insurance

    aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

    SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Wayne A. I. Frederick, M.D., as an advisor to the company. Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023. "We are honored to welcome a distinguished physician executive such as Dr. Frederick as an advisor to aTyr," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Dr. Frederick's clinical background combined with

    1/18/24 8:00:00 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Financials

    Live finance-specific insights

    View All

    Ethos Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    Records full-year revenue of $387.6 million, growing 52% year-over-yearAchieves Net Income of $24.6 million and Adjusted EBITDA of $25.8 million in Q4, reflecting a 22% margin and a 23% Adjusted EBITDA marginDelivers third consecutive year of revenue growth greater than 50% AUSTIN, Texas, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. "We delivered a strong close to 2025 with 65% year-over-year revenue growth in Q4," said Peter Colis, CEO and Co-Founder of Ethos. "Our financial resul

    2/25/26 4:05:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

    Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD currently enrolling. Ended 2023 with $101.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged

    3/14/24 4:00:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

    SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 14, 2024Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI834bef07b22642ae8be51b7

    2/28/24 8:00:00 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/14/24 1:43:55 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/13/24 4:30:17 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/9/24 8:35:54 AM ET
    $LIFE
    Specialty Insurers
    Finance